INAB vs INDP

IN8bio, Inc. vs Indaptus Therapeutics, Inc. — Valuation Comparison 2026

INAB

Biotechnology
IN8bio, Inc.
Quality
3.2
out of 10
Value Trap
36
LOW
Price
$1.80
Last close
Models
7/13
Active
VS

INDP

Biotechnology
Indaptus Therapeutics, Inc.
Quality
2.6
out of 10
Value Trap
36
LOW
Price
$1.44
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType INAB Fair ValueINAB Upside INDP Fair ValueINDP Upside
Bayesian DCF Intrinsic $1.60 -10.9% $0.38 -73.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.60 +99.9% $0.30 -79.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for INAB vs INDP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INAB vs INDP — Which Stock Is More Undervalued?

INAB scores higher with a 3.2/10 quality rating vs INDP's 2.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing IN8bio, Inc. (INAB) and Indaptus Therapeutics, Inc. (INDP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INAB currently trades at $1.80 with a QOC of 3.2/10, while INDP trades at $1.44 with a QOC of 2.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).